Trial · NCT07884669
Biomarker Investigation for Early Gastric Cancer Detection
NCT07884669, Not applicable, Not yet recruiting, Centre Leon Berard
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Biomarker Investigation for Early Gastric Cancer Detection. Trials, record NCT07884669. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07884669
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Biomarker Investigation for Early Gastric Cancer Detection
- NCT number
- NCT07884669
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Centre Leon Berard
- Conditions
- Gastro Oesophageal Cancer
- Interventions
- Saliva sampling, Gastric juice sampling, Blood sampling, Tumor sampling
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Diagnostic performance of salivary and gastric juice biomarker signatures for identifying gastric and gastroesophageal junction cancer (GEC). | At gastroscopy | Presence or absence of gastric or gastroesophageal junction cancer confirmed by histopathological examination following gastroscopy. Biomarker signatures derived from salivary and gastric juice miRNA expression profiles and microbiome composition will be evaluated through positive predictive value to discriminate patients with GEC from patients without GEC. |
| Secondary | Presence of circulating tumor DNA (ctDNA) at baseline. | Baseline (C1D1 pre-dose) | Detection of ctDNA in plasma collected at treatment initiation in patients with non operable GEC. Percentage of participants with detectable ctDNA. |
| Secondary | Longitudinal variation of ctDNA. | From baseline through disease progression (up to 24 months after last patient enrolled) | Changes in ctDNA levels measured in serial plasma samples collected during follow-up. |
| Secondary | Association between ctDNA status and progression-free survival. | Up to 24 months after last patient enrolled | Progression-free survival according to detectable versus non-detectable ctDNA. |
| Secondary | Association between ctDNA status and overall survival. | Up to 24 months after last patient enrolled | Overall survival according to detectable versus non-detectable ctDNA. |
| Secondary | Plasma cytokine concentrations at baseline. | Baseline (C1D1 pre-dose) | Plasma concentrations of cytokines measured using multiplex cytokine assays in patients with non operable GEC. |
| Secondary | Association between cytokine concentrations and progression occurrence. | Up to 24 months after last patient enrolled | |
| Secondary | Progression-free survival according to cytokine concentrations. | Up to 24 months after last patient enrolled | |
| Secondary | Overall survival according to cytokine concentrations. | Up to 24 months after last patient enrolled | |
| Secondary | Tumor transcriptomic profiles measured by RNA sequencing. | At gastroscopy and at disease progression (if available) | Transcriptomic signatures identified using RNA sequencing on tumor samples collected at diagnosis and, if available, at disease progression. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07884669
GET https://conductscience.org/api/trials/v1/NCT07884669/registered